Recipient
Mirexus Biotechnologies Inc.Department
National Research Council CanadaAmount
$200.0K
Province
ONType
Contribution
Agreement Number
172-2018-2019-Q1-907205
Purpose
Mirexus’ proprietary material - trademarked NanoDendrix™ (NaD) is a platform for the development of multiple pharmaceutical applications of safe and natural nanotechnology. Early discovery research has shown selected derivatives can be modified to regulate (either enhance or inhibit) the interferon mediated innate immune response. This further can be used to enable the enhanced production of viruses grown in cell cultures…a potentially disruptive advance in the virus production industry.
Mirexus Biotechnologies Inc. × National Research Council Canada
3 grants totalling $362.3K
Industrial Research Assistance Program – Contributions to Firms
1,000 grants totalling $112.4M
Related Grants
| Recipient | Amount | Program |
|---|---|---|
| Providence Therapeutics Holdings Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Laurent Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Laurent Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |